"Once we roll out the phase 3 clinical trial and with a few months of accelerated data, we hope to apply for the conditional registration approval, for the adoption of the vaccine. We wish to highlight that all vaccines used currently in Malaysia (Pfizer, AstraZeneca, Sinovac) are under the conditional registration approval. None have completed their full trial,"
Firstly, we cannot continue lockdowns indefinitely; the suffering of the poor and middle class is enormous. It has been estimated that an additional two to three million Malaysians have been pushed below the poverty line income during the Covid-19 crisis thus far.
Vaccine, need to burn a lot of woods. Our vaccination centers' process needs further simplification, fast and efficiency, not lets the admin works all jammed at the backend, wasting resources. Waste.. Wasted..continuing.
You are right bro, i will choose to pay and get what can protect me and my family well. Instead of wait the govt to gv..... we need to protect our own family
ceelo ...why your mum send you go study ,you no study good good ? your mum dulan liao
KUALA LUMPUR: Malaysia will take part in phase three clinical trials for a new COVID-19 vaccine manufactured by China's Shenzhen Kangtai Biological Products.
The clinical study will be conducted at eight research centres in Malaysia, said health director-general Dr Noor Hisham Abdullah on Saturday (Jun 5).
>> We are currently conducting the Phase III Clinical Trial in Malaysia and have made an application to the National Pharmaceutical Regulatory Agency for approval to use the vaccines here. If everything goes smooth, we aim to obtain the approval by September or October.
ceelo come kacau punya... any counter with vaccine portfolio sure secured punya ... furthermore YTB have other investment ma , development also finishing liao ~ steady
why blackie barks non stop... by the time clinical trial ends, Malaysia already achieve herd immunity/fully vaccinated. YT sell to who? other SEA countries? Even without approval to be used in Malaysia, you think they can simply sell to other countries without getting each countries approval? Go back to study woi..
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Rickyteo888
5 posts
Posted by Rickyteo888 > 2021-07-07 19:06 | Report Abuse
(吉隆坡7日讯)与中国深圳康泰生物制品股份有限公司(Shenzhen Kangtai Biological Products Co Ltd)合作,在大马供应中国生产新冠疫苗的永大集团(Yong Tai Bhd)表示,计划在9月或10月前向私人界提供疫苗。
该集团此前与康泰生物达成协议,后者将每年供应1000万剂疫苗,如有需要,可以再增加1000万剂。
永大总执行长巫光伦指出,该集团已开始进行实验性疫苗接种。
他在近期的书面采访中向新华社表示:“我们目前正在大马进行第三期临床试验,并已向国家药剂监管组(NPRA)申请批准在这里使用该疫苗。我们的目标是在9月或10月获得批准。”
他还说,该集团计划将康泰生物带到大马,设立一个研发中心和生产工厂,以确保大马有能力和准备好长期或任何情况下应对新冠病毒和未来其他病毒的潜在威胁。
他补充,这也符合大马政府发展生物科技行业的计划,使我国成为本区域的生物科学中心。
“从最新发展来看,我们预计病毒将继续与我们同在。因此,我们认为从长远来看,对疫苗的需求将会很高。”
巫光伦也相信,康泰生物开发的疫苗将被广泛接受,因为与中国另外两家新冠疫苗开发商中国医药集团(Sinopharm)和科兴控股生物技术有限公司(Sinovac)拥有相同的技术平台。
“此外,由于第三期临床试验是在本地进行,为我们提供证明疫苗安全性和有效性的数据,这将对公众更具说服力。”
他指出,中国的疫苗技术是灭活病毒疫苗,记录良好,已被大多数接受。
大马监管机构已有条件批准科兴和康希诺生物(CanSino)分别开发的新冠疫苗,并将其纳入全国疫苗接种计划。
(编译:陈慧珊)
English version:Yong Tai aims to offer Chinese Covid-19 vaccine to private sector by September